november Aktiengesellschaft

EANS-News: november Aktiengesellschaft
November AG subsidiary PROGEN signs exclusive distribution agreement with Asuragen

New: KRAS/BRAF Test for Luminex-User New: AmplideX FMR1 PCR-Assay -------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- New Products/Research & Development/Distribution Subtitle: New: KRAS/BRAF Test for Luminex-User New: AmplideX FMR1 PCR-Assay Cologne (euro adhoc) - PROGEN Biotechnik GmbH, a daughter of the November AG, has signed an exclusive distribution contract for Germany with the U.S.A. based Asuragen Inc., a company focused on personalized medicine and companion diagnostics in the field of oncology and human genetics. PROGEN is now in a position to further expand its product line of multiplexed assays enabling the detection of mutations often found in solid tumors, such as KRAS or BRAF, and fusion transcripts or mutations associated with specific leukemia types or subtypes. These assays incorporate Signature® technology which is optimized for the rapid multiplex analysis of nucleic acid sequences in a single reaction, thus enhancing operational efficiencies through reduced costs and streamlined workflow. The signature® reagents are adapted for use on the Luminex® platform. Additionally, PROGEN offers now two state-of-the-art PCR technologies, developed by Asuragen, for molecular characterization of the trinucleotide repeat in the 5´ region of the fragile X mental retardation (FMR1) gene for routine screening testing. The highly sensitive and time-saving assay is suited for the detection of FMR1 mutations in pre- and postnatal diagnosis and allows initiating early measures for improvement of the living conditions of the patients. PROGEN is thereby extending its product line of biomarker/molecular diagnostics, and Luminex®-based tests for further assays. Thus, the company is consequently pursuing its strategy to offer a broad portfolio of own developed tests as well as products from other manufacturers. About Luminex® Technology The xMAP® (Multi Analyte Profiling) technology developed by Luminex® (www.luminexcorp.com) is an innovative assay platform for a large range of applications. With this technology it is possible to simultaneously test 100 parameters in one test run. Thus, the user saves time and sample material. The technology is based on microscopically small polystyrene beads which are coated with antigens e.g. against different infectious diseases. The automated process allows the beads to identify up to 100 different analytes from one sample. This very sensitive and specific detection enables fast screening tests of many different samples as well as a differential sample analysis. About november AG / PROGEN Biotechnik GmbH november AG, Koeln (www.november.de) is an investment and holding company, listed in the prime standard of the regulated market of the German stock exchange (Deutsche Börse), with special focus on medical technology, biotechnology, and environmental technologies and 100% shareholder of PROGEN Biotechnik GmbH. PROGEN Biotechnik GmbH, Heidelberg (www.progen.de), is manufacturer of in vitro diagnostics (borrelia, hanta virus, FSME) and research reagents (antibodies, polypeptides, AAV, hyperphage, www.hyperphage.com), certified to DIN EN ISO 13485:2007, as well as for the production of multiplex assays for the Luminex® platform. PROGEN is member of the VDGH (German Association of Diagnostic Manufacturers). About Asuragen Inc. Asuragen Inc., Austin, USA, (www.asuragen.com) is a fully integrated molecular diagnostic company focused on personalized medicine and companion diagnostics, with emphasis on mRNA/miRNA applications in oncology. As an FDA-registered medical device manufacturer Asuragen offers cGMP development and manufacturing capabilities available for contract manufacture with a special focus on in vitro transcribed RNA. Asuragen has become a leader in companion diagnostics by discovering and developing predictive and prognostic test for its pharmaceutical and biotechnology partners. end of announcement euro adhoc -------------------------------------------------------------------------------- ots Originaltext: november Aktiengesellschaft Im Internet recherchierbar: http://www.presseportal.ch Further inquiry note: Dr. Dirk Zurek CEO Tel.: +49 (0) 221 82200 520 10 E-Mail: ir@november.de Branche: Biotechnology ISIN: DE000A0Z24E9 WKN: A0Z24E Index: CDAX, Prime All Share, Technology All Share Börsen: Frankfurt / regulated dealing/prime standard Berlin / free trade Stuttgart / free trade Düsseldorf / free trade Hannover / free trade München / free trade

Das könnte Sie auch interessieren: